Alembic Pharma gets USFDA EIR for Panelav facility
New Delhi: Alembic Pharmaceuticals on Friday said it has received establishment inspection report (EIR) from the US health regulator for its Panelav facility in Gujarat.
The company has received EIR from the US Food and Drug Administration (USFDA) for the inspection carried out by them on its general oral solid formulation facility at Panelav, from March 9 to March 13, Alembic Pharmaceuticals said in a filing to the BSE.
"With this, EIR is in place for all our manufacturing facilities for international markets," it added.
Shares of Alembic Pharmaceuticals were trading at Rs 940.05 per scrip on the BSE, up 3.50 per cent from its previous close.
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company headquartered in Gujarat.
Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.